Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

Watchlist Manager
Zentalis Pharmaceuticals Inc Logo
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Watchlist
Price: 1.28 USD 2.4%
Market Cap: 91.9m USD

Wall Street
Price Targets

ZNTL Price Targets Summary
Zentalis Pharmaceuticals Inc

Wall Street analysts forecast ZNTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZNTL is 6.09 USD with a low forecast of 2.22 USD and a high forecast of 10.5 USD.

Lowest
Price Target
2.22 USD
74% Upside
Average
Price Target
6.09 USD
375% Upside
Highest
Price Target
10.5 USD
720% Upside
Zentalis Pharmaceuticals Inc Competitors:
Price Targets
HALO
Halozyme Therapeutics Inc
32% Upside
688331
RemeGen Co Ltd
29% Downside
IDYA
IDEAYA Biosciences Inc
168% Upside
086890
Isu Abxis Co Ltd
96% Upside
ARQT
Arcutis Biotherapeutics Inc
52% Upside
ZYME
Zymeworks Inc
84% Upside
LYTIX
Lytix Biopharma AS
70% Upside
IVACC
Intervacc AB
499% Upside

Revenue
Forecast

Revenue Estimate
Zentalis Pharmaceuticals Inc

The compound annual growth rate of Zentalis Pharmaceuticals Inc's revenue for the next 3 years is -44%.

N/A
Past Growth
-44%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Zentalis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Net Income
Forecast

Net Income Estimate
Zentalis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZNTL's stock price target?
Price Target
6.09 USD

According to Wall Street analysts, the average 1-year price target for ZNTL is 6.09 USD with a low forecast of 2.22 USD and a high forecast of 10.5 USD.

What is Zentalis Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
-44%

The compound annual growth rate of Zentalis Pharmaceuticals Inc's revenue for the next 3 years is -44%.

Back to Top